Israel - englanti - Ministry of Health

unipharm ltd, israel - candesartan cilexetil; hydrochlorothiazide - tablets - hydrochlorothiazide 12.5 mg; candesartan cilexetil 16 mg - candesartan - essential hypertension, where monotherapy with candesartan cilexetil or hydrochlorothiazide is not sufficient

Israel - englanti - Ministry of Health

unipharm ltd, israel - famotidine - tablets - famotidine 10 mg - famotidine - for the treatment and prevention of heartburn and hyperacidity in the upper gastrointestinal tract.

Israel - englanti - Ministry of Health

unipharm ltd, israel - cilazapril - tablets - cilazapril 2.5 mg - cilazapril - cilazapril - a blood pressure lowering agent. chronic heart failure.

Israel - englanti - Ministry of Health

unipharm ltd, israel - cilazapril - tablets - cilazapril 5 mg - cilazapril - cilazapril - a blood pressure lowering agent. chronic heart failure.

Israel - englanti - Ministry of Health

unipharm ltd, israel - cilazapril - tablets - cilazapril 1 mg - cilazapril - cilazapril - a blood pressure lowering agent.chronic heart failure.

Israel - englanti - Ministry of Health

unipharm ltd, israel - donepezil hydrochloride - tablets - donepezil hydrochloride 10 mg - treatment of mild to moderately severe alzheimer`s dementia.

Israel - englanti - Ministry of Health

unipharm trading ltd, israel - pegfilgrastim - solution for injection - pegfilgrastim 10 mg/ml - pegfilgrastim - reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy, given at intervals of 14 days or more, for malignancy. (with the exception of chronic myeloid leukemia and myelodysplastic syndromes).

Israel - englanti - Ministry of Health

unipharm trading ltd, israel - dutasteride; tamsulosin hydrochloride - hard capsule - tamsulosin hydrochloride 0.4 mg; dutasteride 0.5 mg - tamsulosin and dutasteride - treatment of moderate to severe symptoms of benign prostatic hyperplasia (bph).reduction in the risk of acute urinary retention (aur) and surgery in patients with moderate to severe symptoms of bph.

Israel - englanti - Ministry of Health

unipharm trading ltd, israel - everolimus - tablets - everolimus 10 mg - everolimus - evetor is indicated for:- treatment of patients with sega associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection. the effectiveness of evetor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated. - treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease. the safety and effectiveness of evetor in the treatment of patients with carcinoid tumors have not been established. - treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non – steroidal aromatase inhibitor. - treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (tsc), not requiring immediate surgery. the effectiveness of evetor in treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. further follow-up of patients is required to determine long-term outcomes. - treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with vegf-targeted therapy.- treatment of unresectable, locally advanced or metastatic, well-differentiated (grade 1 or grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.

Israel - englanti - Ministry of Health

unipharm trading ltd, israel - everolimus - tablets - everolimus 2.5 mg - everolimus - evetor is indicated for:- treatment of patients with sega associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection. the effectiveness of evetor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated. - treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease. the safety and effectiveness of evetor in the treatment of patients with carcinoid tumors have not been established. - treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non – steroidal aromatase inhibitor. - treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (tsc), not requiring immediate surgery. the effectiveness of evetor in treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. further follow-up of patients is required to determine long-term outcomes. - treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with vegf-targeted therapy.- treatment of unresectable, locally advanced or metastatic, well-differentiated (grade 1 or grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.